4D). This qualitative change might be due to better differentiation of effector/memory T cells in tumor sites after depletion of Treg. This result might not be readily explained by the disappearance of simple competition for IL-7 between pmel-1 cells and CD122+ cells. Rucaparib manufacturer However, our data did suggest that a large amount of exogenous IL-7 (1 μg×10 times, Fig. 5) could mimic certain aspects of CD25 and CD122 depletion. The administration of

a super-physiological amount of IL-7 could have also resulted in other qualitative changes in pmel-1 cells. Together with recent findings that CD122+CD8+ Treg can suppress autoimmunity in the murine Graves’ hyperthyroidism and EAE model independent of lymphopenia-driven proliferation 31, 32, our results indicate that, like CD25+CD4+ Treg, CD122+CD8+ Treg are in fact another group of bona fide natural Treg, whose immune regulatory functions and suppressive mechanisms are waiting to be exploited in the near future. Mice were purchased from the Jackson Laboratory Talazoparib (Bar Harbor, Main)

and from Charles River Laboratories (Wilmington, MA). Pmel-1 transgenic mice, Pmel-1 and GFP double transgenic mice, and IL-15 knockout mice (IL-15−/−) were described before 6. All animal protocols were approved by the Earle A. Chiles Research Institute Animal Care and Use Committee. DC were generated and isolated as described previously 6. Briefly, bone marrow cells were isolated and cultured in complete media supplemented with murine GM-CSF (50 ng/mL) Etofibrate for 8–10 days. Expanded cells were harvested and frozen in mulitple aliquots in LN2. Frozen DC were rapidly thawed at 37°C and pulsed for 2–4 h at 37°C with 10 μg/mL of the appropriate peptide in complete medium. In all experiments, the H-2Db-restricted human gp100 (KVPRNQDWL; hgp-9) was used. Loaded DC were washed with

PBS before injection. The detailed immunotherapy protocol has been described elsewhere 6. Briefly, C57BL/6 mice subcutaneously injected with B16F10 melanoma were subjected to whole body irradiation (500 Gy) on day 5, and adoptively transferred with naïve spleen cells from mice as indicated. In some experiments, CD25+ cells alone or together with NK cells or CD122+ cells (including T cells and NK cells) were depleted using biotin-conjugated anti-CD25, anti-CD122, or anti-NK1.1 antibodies and strepavidin-conjugated MACS MicroBeads (Milenyi Biotec) before adoptive transfer into tumor-bearing mice (n=5–8 per group). Adoptive transfer was followed immediately by s.c. vaccination with 1∼2×106 DC pulsed with hgp-9 peptide. In some experiments, additional DC vaccinations were administrated at indicated intervals. Tumor size was measured three times a week, and mice were sacrificed when one diameter exceeded 150 mm. All experiments were carried out in a blinded and randomized fashion. In some experiments, IL-7 was blocked by injection of mice with 1 mg purified monoclonal anti-IL-7 antibody (clone M25).